ProMIS Neurosciences (PMN) AI Stock Analysis

• Market Cap: $30.48M
• Dividend Yield: N/A
• Average Volume (3M): 819.50K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.36
• Revenue Growth: N/A
• EPS Growth: -273.84%
• Country: US
• Employees: 7
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -6.00
• Shares Outstanding: 2,152,397
• 10 Day Avg. Volume: 1,049,009
• 30 Day Avg. Volume: 819,497
• PEG Ratio: -0.08
• Price to Book (P/B): 1.49
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.90
• Enterprise Value/Market Cap: 0.10
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -0.11
• 1Y Price Target: $19.33
• Price Target Upside: 138.10% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $14.50 ▲(78.57% Upside)

The score is held back primarily by weak financial performance (no revenue, sizable losses, and significant ongoing cash burn), which implies reliance on external funding and potential dilution. Technicals are strong but overbought, supporting momentum while adding pullback risk. Corporate events improve the outlook by extending runway and reducing listing risk, but negative-earnings valuation metrics limit support.

Positive Factors

PIPE Financing Extends Runway

A $75M PIPE materially extends operational runway into 2028, enabling the company to finance planned PMN310 development and regulatory milestones without immediate dilution pressures. This structural capital reduces near-term financing execution risk and lets management focus on clinical delivery.

Advancing PMN310 Clinical Program

Clear timing and funding for blinded 6‑ and 12‑month readouts provide concrete de‑risking milestones. Positive clinical outcomes would materially strengthen the company’s long‑term commercial prospects and validate its therapeutic approach, impacting strategic partnerships and future development priorities.

Regained Nasdaq Listing Compliance

Restoring Nasdaq compliance reduces structural listing risk and preserves access to public capital markets, institutional investors, and liquidity. Continued listing supports future financing and partnership opportunities, which is critical for capital‑intensive clinical development over multiple years.

Negative Factors

Pre‑revenue with Sustained Losses

Being pre‑revenue and deeply loss‑making is a durable structural constraint: the business must convert clinical programs to approved products to become self‑sustaining. Until then the company depends on capital markets and partnerships, increasing execution risk if trials underperform or timelines slip.

High Operating Cash Burn

Consistent ~‑$27M annual cash burn means the company cannot self‑fund development from operations. This persistent negative cash generation forces recurring external financings, which can dilute shareholders, constrain strategic optionality, and pressure prioritization of programs over the medium term.

Eroding Shareholders' Equity

A meaningful decline in equity reflects cumulative losses and/or prior financings and signals limited internal capital buffers. With low equity and no operating cash inflows, the company remains exposed to dilution risk and may need further equity issuances to sustain development timelines and strategic initiatives.

ProMIS Neurosciences Business Overview & Revenue Model

Company Description

ProMIS Neurosciences (PMN) is a biotechnology company focused on the discovery and development of precision therapeutics for neurodegenerative diseases, particularly Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company utilizes its proprietary technology platform to selectively target misfolded proteins implicated in these diseases, aiming to develop disease-modifying treatments. ProMIS Neurosciences operates primarily in the biotechnology and pharmaceutical sectors, leveraging advanced scientific research to address unmet medical needs in neurodegenerative conditions.

How the Company Makes Money

ProMIS Neurosciences generates revenue through a combination of research and development collaborations, licensing agreements, and potential future sales of its proprietary therapeutics. The company may receive upfront payments, milestone payments, and royalties from its partnerships and licensing deals. Additionally, as its products advance through clinical development and potentially receive regulatory approval, ProMIS may earn revenue from product sales. The company's revenue model is highly dependent on successful clinical trials, strategic alliances, and partnerships with larger pharmaceutical companies to commercialize its therapies.

ProMIS Neurosciences Financial Statement Overview

Summary

Overall fundamentals are weak for a pre-revenue biotech: revenue is $0, TTM net income is about -$29.3M with EBIT about -$35.4M, and operating/free cash flow are both about -$27.2M (high ongoing cash burn). The main offset is a conservative balance sheet with $0 debt and still-positive equity (~$9.2M), though equity has been declining, implying continued financing/dilution risk.

Income Statement

PMN remains a pre-revenue biotech with revenue at $0 in both TTM (Trailing-Twelve-Months) and recent annual periods, so losses are driven by operating spend rather than product economics. Profitability is weak in TTM with net income of about -$29.3M and EBIT of about -$35.4M, a notable deterioration versus 2024 (positive net income ~$2.8M despite negative EBIT). The 2024 profitability appears non-recurring/volatile given the sharp swing back to sizable losses in TTM.

Balance Sheet

The balance sheet is relatively conservative from a leverage standpoint with total debt at $0 in TTM and in recent annual reports (and a prior debt balance in 2021 that has since been eliminated). Stockholders’ equity remains positive at ~$9.2M in TTM, though it has declined from ~$16.5M in 2024, consistent with ongoing cash burn. Returns to shareholders are pressured by losses, with TTM return on equity deeply negative, highlighting dilution/financing risk if losses persist.

Cash Flow

Cash generation is weak, with operating cash flow at about -$27.2M in TTM (similar to 2024 at about -$27.2M), indicating a high ongoing cash burn rate. Free cash flow is also about -$27.2M in TTM, and while free cash flow growth is shown as positive in TTM, the absolute level remains meaningfully negative. Cash flow does not currently self-fund operations, implying reliance on external capital to continue development activities.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	―	1.56K
Gross Profit	0.00	0.00	-10.44M	0.00	―	-3.18M
EBITDA	-29.28M	2.86M	-17.81M	-17.77M	-9.33M	-5.65M
Net Income	-29.28M	2.78M	-17.51M	-18.06M	―	-5.66M
Balance Sheet
Total Assets	21.46M	18.91M	13.62M	9.38M	22.44M	1.38M
Cash, Cash Equivalents and Short-Term Investments	15.43M	13.32M	12.63M	8.01M	21.48M	1.11M
Total Debt	0.00	0.00	0.00	0.00	4.94M	0.00
Total Liabilities	12.27M	2.42M	9.87M	11.20M	15.28M	2.40M
Stockholders Equity	9.19M	16.49M	3.75M	-1.82M	7.16M	-1.02M
Cash Flow
Free Cash Flow	-27.20M	-27.18M	-10.84M	-17.04M	-9.45M	-4.46M
Operating Cash Flow	-27.20M	-27.18M	-10.84M	-17.03M	-9.44M	-4.35M
Investing Cash Flow	-678.00	-693.00	-1.35K	-1.98K	95.93K	-111.88K
Financing Cash Flow	21.27M	27.88M	17.75M	6.49M	25.63M	3.83M

ProMIS Neurosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.12
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PMN, the sentiment is Positive. The current price of 8.12 is below the 20-day moving average (MA) of 9.04, below the 50-day MA of 8.56, and below the 200-day MA of 11.91, indicating a bullish trend. The MACD of 1.02 indicates Negative momentum. The RSI at 82.84 is Negative, neither overbought nor oversold. The STOCH value of 78.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PMN.

ProMIS Neurosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PMN	52 Neutral	$30.48M	-0.76	-355.80%	―	―	-273.84%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NERV	50 Neutral	$175.69M	-2.19	―	―	―	-323.61%
ANVS	46 Neutral	$71.56M	-1.82	-246.14%	―	―	62.84%
NRSN	44 Neutral	$27.32M	-1.57	―	―	―	31.09%
IMRN	38 Underperform	$7.96M	-1.59	-49.00%	―	47.17%	26.84%

ProMIS Neurosciences Corporate Events

ProMIS Neurosciences Announces $75 Million PIPE Financing

On January 30, 2026, ProMIS Neurosciences announced it had entered into a private investment in public equity financing, signing a securities purchase agreement on January 29, 2026 with new and existing institutional and accredited investors to raise approximately $75 million in upfront gross proceeds through the sale of 6,815,296 common shares and accompanying warrants, with the potential to raise up to a total of about $175 million if all warrants are exercised. The PIPE, co-led by Janus Henderson and Ally Bridge Group and also involving several specialized healthcare investors plus ProMIS management and directors, is expected to close on February 3, 2026 and extend the company’s cash runway into 2028, funding completion of its Phase 1b Alzheimer’s study of PMN310, advancing a subcutaneous formulation of the drug, and supporting key clinical milestones, including blinded six‑month top-line data anticipated in mid‑2026 and 12‑month top-line data toward the end of 2026.

The most recent analyst rating on (PMN) stock is a Hold with a $11.50 price target. To see the full list of analyst forecasts on ProMIS Neurosciences stock, see the PMN Stock Forecast page.

ProMIS Neurosciences Regains Nasdaq Compliance

On December 12, 2025, ProMIS Neurosciences Inc. announced it has regained compliance with Nasdaq’s $1.00 minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market. This follows a year-long period of non-compliance, during which the company was granted additional time to meet the requirement, ultimately achieving the necessary bid price through strategic measures such as a potential reverse stock split.

The most recent analyst rating on (PMN) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on ProMIS Neurosciences stock, see the PMN Stock Forecast page.

ProMIS Neurosciences Announces Reverse Stock Split

On November 24, 2025, ProMIS Neurosciences announced a one-for-twenty-five reverse stock split of its common shares, which will take effect on November 28, 2025. This decision, approved by the board of directors, aims to address the company’s non-compliance with Nasdaq’s minimum bid price requirement, potentially enhancing the market price of its shares and ensuring continued listing on the Nasdaq Capital Market.

The most recent analyst rating on (PMN) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on ProMIS Neurosciences stock, see the PMN Stock Forecast page.

ProMIS Neurosciences Approves Key Shareholder Proposals

On November 17, 2025, ProMIS Neurosciences Inc. held a special meeting of shareholders to vote on two key proposals. The first proposal, which was approved, involved authorizing a potential share consolidation at a ratio determined by the Board within a year. The second proposal, also approved, allowed for the adjournment of the meeting if necessary to solicit additional proxies. These decisions could impact the company’s stock structure and shareholder engagement strategies.

The most recent analyst rating on (PMN) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on ProMIS Neurosciences stock, see the PMN Stock Forecast page.